{'fraction_non_alphanumeric': 0.053837342497136315, 'fraction_numerical': 0.048109965635738834, 'mean_word_length': 4.905405405405405, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In-vitro activity of azithromycin against Chlamydia trachomatis.

We evaluated the efficacy of azithromycin, erythromycin and doxycycline in controlling in-vitro propagation of Chlamydia trachomatis in HeLa 229 cells. Eight recent clinical isolates of C. trachomatis and two fast-growing strains were tested with inocula of 10(3)-10(5) inclusion forming units per well of a 96-well microtitre plate. C. trachomatis inclusions were detected by an immunoperoxidase-antiperoxidase procedure (PAP), including a genus-specific monoclonal antibody. MIC ranges were 0.064-0.25 mg/l azithromycin, 0.064-0.128 mg/l erythromycin and 0.016-0.064 mg/l doxycyline; MBC ranges were 2-8 mg/l azithromycin, 4-64 mg/l erythromycin and 0.5-8 mg/l doxycycline. Since azithromycin appears to be effective against C. trachomatis, clinical studies in sexually transmitted diseases are indicated.